Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) is now available.
ImmuneOnco Biopharmaceuticals announced that Dr. Tian Wenzhi, the company’s executive director, CEO, and chairman, has increased his shareholding by purchasing 150,000 H shares in the open market. This move, which reflects Dr. Tian’s confidence in the company’s growth prospects, raises his total shareholding to 28.49% of the company’s issued share capital. The announcement suggests potential future increases in his stake, indicating a strong belief in the company’s future performance.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on developing innovative cancer immunotherapies. The company operates in the healthcare industry, primarily dealing with biopharmaceutical products aimed at treating cancer.
YTD Price Performance: 5.04%
Average Trading Volume: 8,306,115
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.97B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.